Form 4 for CRL Charles River Laboratories
Accepted 2025-11-07 00:00:00 ET · period of report 2025-11-06 · accession 0001100682-25-000045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 | 2025-11-06 | CRL | Knell Michael Gunnar | CAO, CSVP, Interim CFO | A - Grant | $170.88 | +2,926 | 13.5K | +28% | +$500.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-06 | A | A | 2,926 | $170.88 | 13,460 | D | — | — | (F1) 50% of the unvested restricted stock units vest on November 6, 2026, with the remaining 50% vesting on November 6, 2027. |